LIVE
Ethereum Reached Record Q1 On-Chain Users and Transaction Volume: ReportMorgan Stanley's Ethereum, Solana ETFs Target 0.14% FeeCME Sues CFTC Over Kalshi Perpetual FuturesKraken Launches In-App Trading for 2,500+ Solana TokensBitcoin Rodney Pleads Guilty in $1.8B HyperFund Fraud CaseCME to Sue CFTC Over Approval of Crypto Perpetual FuturesWorld Datacentre Summit Philippines 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesARK Invest Buys $18.4 Million in Coinbase Shares Across Three ETFsWorld Datacentre Summit Malaysia 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesKentucky Files Lawsuits Against Kalshi and PolymarketEthereum Reached Record Q1 On-Chain Users and Transaction Volume: ReportMorgan Stanley's Ethereum, Solana ETFs Target 0.14% FeeCME Sues CFTC Over Kalshi Perpetual FuturesKraken Launches In-App Trading for 2,500+ Solana TokensBitcoin Rodney Pleads Guilty in $1.8B HyperFund Fraud CaseCME to Sue CFTC Over Approval of Crypto Perpetual FuturesWorld Datacentre Summit Philippines 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesARK Invest Buys $18.4 Million in Coinbase Shares Across Three ETFsWorld Datacentre Summit Malaysia 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesKentucky Files Lawsuits Against Kalshi and Polymarket
Homepage/News/Windtree Therapeutics to Delist from Nasdaq,...
NEWS

Windtree Therapeutics to Delist from Nasdaq, Moves to OTC

BY Solomon M.·2 MIN READ·AUGUST 21, 2025

Windtree Therapeutics, BNB partner, to be delisted from Nasdaq due to noncompliance and will transition to OTC trading.

Windtree Therapeutics Inc., a BNB treasury partner, is set to be delisted from Nasdaq on August 21, 2025, for noncompliance with minimum listing rules, transitioning to OTC trading.

KEY FINDINGS - EVIDENCE LEVEL: MULTI-SOURCE
1Key sections mapped in this report
0Internal references connected to related coverage
3External source domains cited in the article
2 minEstimated time to read the full report
Key Points:
  • Nasdaq delists Windtree Therapeutics for not meeting listing requirements.
  • Shares will transition to OTC, maintaining liquidity.
  • BNB records no adverse impact after Windtree’s delisting.
windtree-therapeutics-to-delist-from-nasdaq-moves-to-otc
Windtree Therapeutics to Delist from Nasdaq, Moves to OTC
MAGA

The delisting impacts Windtree’s shareholders but has no adverse effect on BNB, which reached a record high, demonstrating resilience amidst the company’s stock market challenges.

Windtree Therapeutics, a treasury partner to BNB, will be delisted from Nasdaq. The delisting results from noncompliance with Nasdaq’s minimum share price rule, prompting the shift to over-the-counter trading. This action affects the company’s market presence.

The delisting decision was communicated by Nasdaq on August 19, 2025. Windtree Therapeutics intends to continue operations unaffected. The move to OTC markets is pending and aims to sustain trading activities under its current ticker.

The impact on Windtree’s market is significant but operationally negligible. Shareholders face reduced liquidity as shares migrate to the OTC space. BNB, however, remains stable, reflecting resilience amidst its partner’s delisting actions.

Financially, Windtree maintains its corporate functions despite the delisting. No capital withdrawals or funding alterations have been reported. BNB’s market performance has not faltered, reaching new highs despite the transition of its treasury partner.

“On August 19, 2025, Windtree Therapeutics Inc. (the ‘Company’) was notified by The Nasdaq Stock Market LLC (‘Nasdaq’) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on August 21, 2025…” — Windtree Therapeutics, SEC Form 8-K

Historically, similar delistings have not disrupted linked crypto ecosystems. The continuity of trading for Windtree in the OTC market suggests minimal downstream effects on associated digital assets.

Potential outcomes include changes in investor sentiment and adjustments to Windtree’s financial strategies. Previous trends indicate OTC trading as a viable alternative for maintaining share circulation and investor engagement, reinforcing market stability.

Disclaimer:

The content on The CCPress is provided for informational purposes only and should not be considered financial or investment advice. Cryptocurrency investments carry inherent risks. Please consult a qualified financial advisor before making any investment decisions.

SOURCE TRANSPARENCY
  • External Source - Referenced domain: buy.magacoinfinance.com
  • External Source - Referenced domain: sec.gov
  • External Source - Referenced domain: windtreetx.com
  • Byline - Reported by Solomon M.
  • Coverage Desk - Primary editorial category: News
  • Media Asset - Featured image served from the WordPress media library
Windtree Therapeutics to Delist from Nasdaq, Moves to OTC | TheCCPress